The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) treated with immune checkpoint inhibitors (ICIs).
 
Ahmet Yildirim
No Relationships to Disclose
 
Mengting Wei
No Relationships to Disclose
 
Yuan Liu
No Relationships to Disclose
 
Rohit Vivek Goswamy
No Relationships to Disclose
 
Yujin Choi
No Relationships to Disclose
 
Jacqueline T Brown
Consulting or Advisory Role - Exelixis; Xencor
Research Funding - Hookipa Pharma (Inst); Medicenna (Inst); Merck (Inst); Surface Oncology (Inst); Xencor (Inst)
 
Bassel Nazha
Honoraria - Intellisphere, LLC (Onclive)
Consulting or Advisory Role - Cardinal Health; Exelixis; IntrinsiQ
 
Dylan J. Martini
No Relationships to Disclose
 
Caitlin Hartman
No Relationships to Disclose
 
Greta Russler McClintock
No Relationships to Disclose
 
Tony Zhuang
No Relationships to Disclose
 
Haydn Kissick
No Relationships to Disclose
 
Wayne B. Harris
No Relationships to Disclose
 
Bradley Curtis Carthon
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Gilead Sciences; Immunomedics
Research Funding - Alkermes (Inst); MedImmune (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Omer Kucuk
No Relationships to Disclose
 
Viraj A. Master
Honoraria - Ethicon; Exelixis
 
Mehmet Asim Bilen
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; SeaGen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)